We also need to consider the effect of fibrosis on the L/S ratios. By multivariate analysis, fibrosis stage did not influence the L/S ratio as shown in Tables 2 and 3. However, L/S ratios tended to show increased values in advanced stage NASH as shown in Figure 5. Though the statistical differences were not obtained in this studied population, there is a possibility that severity of fibrosis influences the L/S ratios. We should take into account these PS-341 molecular weight facts and cases be increased to elucidate the real relationship between
fibrosis and L/S ratio in the future study. The limitation of this study was that relatively small numbers of patients were studied, and further analysis and validation would be desirable. In conclusion, we analyzed the relationship between L/S ratio and histological findings to
accurately diagnose fatty liver by imaging such as CT. We identified that the optimal cut-off value of L/S ratio to exclude steatosis was 1.1, and the AUROC for the diagnosis of steatosis was 0.886. Also, we identified the L/S ratio equivalent to histologically diagnosed steatotic grades. Accordingly, L/S ratio on CT would be useful for the detection of steatosis, speculating the Tanespimycin datasheet steatotic grade, and even for monitoring the disease progression or the response to therapy. “
“The role of clinical symptoms, transabdominal ultrasound scan (USS), and liver function tests
(LFTs) in evaluating common bile duct (CBD) stones in patients suspected to have pancreatobiliary disease has been studied. However, it is unclear whether these predictive models are useful in different age cohorts. The aim of this study is to investigate the clinical presentations from different age cohorts with and without CBD stones. Four hundred and forty-three patients with pancreatobiliary Oxalosuccinic acid diseases were divided into cohorts according to decades as follows: young (Y, 18–64 years old, n = 143), young-old (YO, 65–74 years old, n = 168), old-old (OO, 75–84 years old, n = 97), and very old (VO, ≥ 85 years old, n = 35). The clinical symptoms, LFTs, and USS findings were demonstrated and compared among patients. Y- and YO-group patients were more likely to develop symptoms such as biliary colic in the presence of CBD stones. The proportion of abnormal serum aspartate aminotransferase and alanine aminotransferase were significantly greater in Y-, YO-, and OO-group patients with than in those without CBD stones. Sensitivity of USS for CBD stones in Y: 0.15; YO: 0.45; OO: 0.57; and VO: 0.68. Accuracy of USS for detected CBD stone in Y: 48%; YO: 62.5%; OO: 70.1%; and VO: 71.4%. Combined evaluation of clinical symptoms, biochemical and USS findings may help predict the presence of CBD stones. In Y, YO, and OO patients with CBD stones, the incidences of abnormal LFTs were higher.